Contents lists available at ScienceDirect

Journal of Cancer Policy

journal homepage: www.elsevier.com/locate/jcpo

High-cost cancer imaging: Opportunities for utilization management

Timothy P. Copeland*, Benjamin L. Franc

Department of Radiology and Biomedical Imaging, University of California, San Francisco, 185 Berry Street, San Francisco, CA, United States

ARTICLE INFO

Article history: Received 1 August 2016 Accepted 12 December 2016 Available online 14 December 2016

Keywords: Diagnostic imaging Utilization Radiology Medical oncology Evidence-based practice

ABSTRACT

Objectives: To retrospectively evaluate utilization of high-cost cancer imaging to clarify the extent to which variations in provider preferences drive imaging utilization.

Study design: At a United States academic cancer center, 4,605 patients were identified with 29,740 oncologist ordered tomographic imaging studies. Patients' dates of death ranged from January 2000 through December 2014. Imaging was restricted to CT, MR, and PET/PET-CT. Outcome variables were total imaging per patient and total imaging per patient by a single oncologist. The number of ordering oncologists per patient, patients receiving imaging in the final year of life, and patients receiving imaging ordered by a high-ordering oncologist were the predictors of interest.

Methods: Zero-truncated negative binomial regressions were used to model collective and individual oncologist per patient imaging counts, with the exposure period defined as the number of days from diagnosis to death.

Results: Patients with imaging ordered by one of the high-ordering medical oncologists predicted nearly a two-fold increase in total images from diagnosis to death (IRR, 1.93; 95% CI, 1.67–2.23). Increasing numbers of providers (2, 3, 4+ ordering oncologists) were associated with greater collective per patient imaging (IRRs 1.65, 2.19, 2.33). Mean imaging intensity increased in a linear manner as temporal proximity to death decreased, from 12 months pre-mortem to death, and imaging in the final year of life was associated with greater per patient imaging (IRR, 0.25; 95% CI, 0.23–0.27).

Conclusion: These findings suggest heterogeneous provider ordering preferences and lapses in care coordination are drivers of high-cost cancer imaging utilization.

© 2016 Elsevier Ltd. All rights reserved.

1. Introduction

The costs of cancer care are escalating, both domestically and internationally, calling into question the long-term sustainability of health systems and health care practices in high-income countries [1,2]. The escalating costs of diagnostic technologies have continued to exceed increases in other cancer care expenditures, drawing greater attention to utilization patterns of high-cost tomographic imaging [3–5]. The extent to which benefits are derived from greater rates of imaging utilization has not been studied extensively in oncology, but studies have generally been unable to confirm benefits from increased tomographic imaging and associated treatments during the end of life [6,7]. Given that one-third of end-of-life cancer care expenditures concentrate in the last month due to escalating treatment aggressiveness [8], exploration of imaging intensity within this period may reveal opportunities to

* Corresponding author at: Radiology & Biomedical Imaging, Box 0946, 185 Berry Street B N, Room 350, San Francisco, CA 94143, United States.

E-mail address: Timothy.Copeland@ucsf.edu (T.P. Copeland).

http://dx.doi.org/10.1016/j.jcpo.2016.12.004 2213-5383/© 2016 Elsevier Ltd. All rights reserved. improve healthcare value through the elimination of imaging that does not lead to improved outcomes.

2. Patients and methods

We conducted a retrospective analysis of cancer patients' tomographic imaging utilization from diagnosis to death at an academic comprehensive cancer center in California to explore variations in oncologist ordering. Collective and individual oncologist imaging rates per patient were the outcomes of interest. Collection of data for this study was approved by the institutional review board and did not require patient consent.

2.1. Study population and data sources

The radiology information system (RIS) at an academic comprehensive cancer center was queried to identify all computed tomography (CT), magnetic resonance (MR), and positron emission tomography (PET) records containing an ICD-9 code associated with malignant neoplasm. Data retrieved from the RIS records included patient medical record number, social security number,



Original Research



gender, race, date of birth, date of imaging study, ordering provider, and exam description, which indicated imaging modality.

Patients with oncologic imaging studies were matched to California Department of Public Health death records, and deceased patients with dates of death from January 2000 to December 2014 were matched to the cancer center's institutional registry to provide clinical and treatment variables. Patients were classified by year of death into one of three 5-year ranges (i.e. 2000–2004, 2005–2009, and 2010–2014) to account for changes in imaging modality availability and utilization trends [9–11].

2.2. Provider identification

To focus our analysis on oncologists with long-term affiliation with the cancer center, we excluded imaging studies if ordered by an oncologist with fewer than 50 patients expiring between January 2000 and December 2014. The resulting oncologists' practice areas were identified as medical oncology, surgical oncology, or radiation oncology. Imaging ordered by non-oncologists was not included in the study sample.

We generated several provider related variables, including: (1) A categorical variable for number of ordering oncologists per patient for which patients were classified as having one, two, three, or four or more ordering oncologists; (2) a dichotomous variable denoting whether patients were imaged in their final year of life; and (3) a dichotomous variable denoting whether patients received imaging ordered by one of the high-ordering oncologists. High-ordering oncologists were defined as oncologists who imaged at least 50 patients and were above the 90th percentile of mean per patient imaging intensity.

2.3. Outcomes

The primary outcomes of our regression models were total imaging per patient, referred to herein as collective ordering; and total imaging ordered per patient by a single oncologist, referred to herein as individual ordering. Collective ordering was defined as the sum of CT, MR, and PET image counts for a given patient from diagnosis to death. Individual ordering was defined as total imaging within unique combinations of patients and ordering providers. To provide further insight into oncologic imaging utilization in the end of life, mean per-patient imaging intensity in 3-month treatment periods from 12 months pre-mortem to death were calculated. Zero values (i.e. no imaging in a 3-month period) were included in the calculation of the means.

2.4. Statistical analysis

Zero-truncated negative binomial regressions were used to model collective and individual oncologist per patient imaging counts, with the exposure period defined as the number of days from diagnosis to death. In addition to provider variables, independent variables for patient characteristics included TNM stage at diagnosis, cancer recurrence, year of death range, and treatment counts (surgery, radiation, and chemotherapy). Both models were adjusted for sex, age at death, race, and cancer type. Regression results were reported as incident rate ratios (IRRs). Kruskal-Wallis tests were used to assess variation between three year-of-death time periods, as well as variation in per patient imaging counts between oncologist practice areas. All statistical analyses were conducted using Stata SE version 13.1 (StataCorp LP, College Station, Texas).

Table 1

Patient Demographics and Characteristics.

Age at Death18-392976%40-642196%40-64211046%Sex65 +211046%SexMale237852%Female222748%RaceWhite34157%Black65 +1132%Other/Unknown6414%Pacific Islander1132%Other/Unknown1483%Cancer TypeHead, Neck, & Throat3037%Gastrointestinal135930%Respiratory98821%Male Reproductive1114%Breast3648%Male Reproductive1114%Female Reproductive11111%Breast3648%Male Reproductive11111%Breast3643%Year of Death1200-200477517%Year of DeathI11%11%In11011572%In11111572%In11111572%In11111572%Ordering Oncologists per Patient1111%In11011572%In11011572%In11011115%In200-200913131%In1161152%In1161152%In1161152%In116		Total Patients	N	%
Age at Death18–392976%40-64219848%65 +210848%SexMale2375%Female2385%RaceWhite341574%Black2606%Asian64014%Pacific Islander1132%Cancer TypeHead, Neck, & Throat3037%Gastrointestinal3037%Gastrointestinal3031%FeastMale Reproductive3048%Male Reproductive1414%FeastMale Reproductive1141%Male Reproductive1311%1%Gastrointestinal3121%1%FeastMale Reproductive1411%Male Reproductive1311%1%Gastrointestinal3131%1%Male Reproductive1411%1%Gastrointestinal1521%1%Male Reproductive1411%1%Male Reproductive1411%1%Male Reproductive1411%1%Male Reproductive1411%1%Male Reproductive1411%1%Male Reproductive1411%1%Male Reproductive1411%1%Male Reproductive1411%1%Male Reproductive1411%1%Male Reproductive1411%1%<			4605	100%
18-392976%40-64219848%65 +25065SexMale237852%RaceWhite341574%Black2656%Asian66414%Pacific Islander1312%Cancer TypeHead, Neck, & Throat303Cancer TypeKasian66414%Back2056%Asian64414%Pacific Islander1312%Cancer TypeKasian303Cancer TypeFead, Neck, & Throat303Castrointestinal135930%Respiratory98821%Bone, Skin, & Connective Tissue11%Breast3648%Male Reproductive1199%Kidney & Bladder1844%Female Reproductive1199%Year of Death11%11%Year of DeathI11%INM Stage at DiagnosisI11%INM Stage at DiagnosisI11%INM Stage at DiagnosisI11%Inaccer RecurrenceI100Incologists10%20%Inace Reproductive11%3%Inace Reproductive11%Inace Reproductive11%Inace Reproductive11%Inace Reproductive11%Inace Reproductive11%Inace Reproductive11%Inace Reproductive11%Inace Reprodu	Age at Death			
A0-64219848%SexMale237852%Female222748%RaceWhite341574%Black2656%Asian66414%Pacific Islander1132%Other/Unknown1132%Cancer TypeHack, & Afnoat139Kasian66414%Pacific Islander1132%Gastrointestinal1397%Gastrointestinal1397%Male Reproductive11311%Breast3648%Male Reproductive11411%Female Reproductive11411%Female Reproductive11411%Boone Skin, & Connective Tissue11%Boone Skin, & Connective Tissue11%Boone Skin, & Connective Tissue11%Female Reproductive11%Female Reproductive11%Stain & CNS3111%Boone Skin, & Donnective Tissue11%Jouro-200421%11%Jouro-200477517%Juit111725%Juit111725%Juit115725%Juit111725%Juit115725%Juit115725%Juit115725%Juit115725%Juit115725%Juit115725%Juit115725%Juit1157 <t< td=""><td></td><td>18-39</td><td>297</td><td>6%</td></t<>		18-39	297	6%
SexMale Female211046%SexMale Female222748%RaceWite341574%Black2656%Asian66414%Pacific Islander1132%Other/Unknown1483%Cancer TypeHead, Neck, & Throat Gastrointestinal3037%Respiratory98821%Bone, Skin, & Connective Tissue Breast50111%Breast6448%Male Reproductive1714%Female Reproductive1714%Female Reproductive1846%Brain & CNS111%Bood & Lymphatic235%Year of Death100-20042395%TIM Stage at DiagnosisI1%1%In111115725%Orderring Oncologists per PatientIn11%Innocologists21%1%1%Ancer recurrence Single case without remission31%1%Ordering Oncologists per Patient1000 (20%)24%Innaging in the Final Year of In311%25%Imaging ordered31%25%25%Innaging Ordered31%31%Innaging Ordered31%31%Inaging Ordered31%31%Innaging Ordered31%31%Innaging Ordered31%35%Innaging Ordered34%34%Innaging Ordered34%34% <tr< td=""><td></td><td>40-64</td><td>2198</td><td>48%</td></tr<>		40-64	2198	48%
SexMale23782378Female23782378RaceWhite341574%Black2656%Asian664245Pacific Islander1132%Other/Unknown1483%Cancer TypeHead, Neck, & Throat303Male Reproductive30411%Breast364364Male Reproductive11111%Breast3648%Male Reproductive11811%Breast3648%Male Reproductive1111%Brade Reproductive1		65 +	2110	46%
Male237852%Female237852%Female200074%Black2656%Asian66414%Pacific Islander11327Other/Unknown11327Cancer TypeHead, Neck, & Throat303Cancer Type888215Back501115Back301116Back689216Bone, Skin, & Connective Tissu301Breast3648%Male Reproductive111Breast364Kidney Bladder184Endocrine & Neuroendocrine52Kidney Bladder113Brain & CNS31Brain & CNS31Perane Reproductive171Parine & Scoope133Year of Death2005-2009TIM Stage at Diagnosis1Inamine Conserver133Cancer Recurrence113Init115Single case without remission302Ordering Oncologists per Parine200-2004Incologists313Incologists313Incologists314Incologists315Incologists314Incologists315Incologists316Incologists316Incologists316Incologists312Incologists312Incologists312Incologists314Incologists315	Sex			
Female222748%RaceWhite341574%Black2656%Asian66414%Pacific Islander1182%Other/Unknown1483%Cancer TypeHead, Neck, & Throat3037%Gastrointestinal135930%Respiratory98821%Bone, Skin, & Connective Tissus50111%Breast3648%Kidney & Bladder1144%Emoderine & Neuroendocrine521%Brain & CNS311%Bood & Lymphatic235%Year of Death200-200477517%TMM Stage at DiagnosisI130%3%II11%200-200477517%Qioto-200477517%20%III12020923%TMM Stage at DiagnosisI11%13%IIICancer Recurrence11%25%IIIIII11%25%Ordering Oncologists per ParietiIncologist33%IIIGancologists10%24%Qioncologists10%24%III10021%III20020%III20%20%III20%20%III20%20%III20%20%III20%20%III20%20%III20%20%III20%		Male	2378	52%
RaceWhiteStais74%Black2656%Asian66414%Pacific Islander1132%Other/Unknown1483%Cancer TypeHead, Neck, & Throat30%Respiratory98821%Bone, Skin, & Connective Tissue50111%Breast3648%Male Reproductive1714%Female Reproductive1744%Female Reproductive1741%Female Reproductive1741%Female Reprodu		Female	2227	48%
White341574%Black2656%Asian6414%Pacific Islander1132%Other/Unknown1483%Cancer TypeHead, Neck, & Throat303Gastrointestinal30530%Respiratory98821%Bone, Skin, & Connective Tissue50111%Breast3648%Male Reproductive1714%Endocrine & Neuroendocrine521%Brain & CNS311%Bood & Lymphatic2335%Year of Death2000-200413111%2005-2009143131%2005-2009143131%2010-201423995%TMM Stage at DiagnosisI11575%Inflaming1021%1%Quotacce meter1131%1%Quotacce meter1131%1%Inflaming1572%1%Inflaming1572%1%Inflaming1572%1%Quotacce without remission3092%Inflaming1572%1%Inflaming15126%Inflaming15122%Inflaming15122%Inflaming15122%Inflaming15122%Inflaming15123%Inflaming15123%Inflaming15123%Inflaming15123	Race			
Black2656%Asian66414%Pacific Islander1483%Cancer TypeHead, Neck, & Throat3037%Gastrointestinal135930%Respiratory50111%Breast3648%Male Reproductive1714%Female Reproductive1714%Female Reproductive1714%Endocrine & Neuroendocrine521%Brain & CNS311%Blood & Lymphatic2335%Year of Death2000-20042395%TNM Stage at DiagnosisI11%11%Intananto10021%11%Intananto2009201411%Cancer RecurrenceI11%11%Intananto200201421%Single case without remission16%16%Intonclogists per Patient10ncologists20%Intananto31021%21%Aronorologists per Patient10ncologists20%Intananto31021%21%Single case without remission31021%Intananto31021%21%Intananto31021%Intananto31021%Intananto31021%Intananto31021%Intananto31021%Intananto31021%Intananto31021%Intananto31021%<		White	3415	74%
Asian66414%Pacific Islander1182%Other/Unknown1882%Cancer TypeHead, Neck, & Throat3037%Gastrointestinal135930%Respiratory98821%Bone, Skin, & Connective Tissue6048%Bone, Skin, & Connective Tissue7144%Female Reproductive1714%Female Reproductive1949%Kidney & Bladder1844%Endocrine & Neuroendocrine521%Brain & CNS3131%Boole & Lymphatic23352%Year of Death200-200477517%Year of Death111%31%Inflant75016%Inflant75016%Inflant75016%Inflant75016%Inflant75016%Inflant115725%Inflant115725%Inflant115725%Inflant115725%Inflant115725%Inflant115725%Inflant115725%Inflant115825%Inflant115925%Inflant115025%Inflant115725%Inflant115725%Inflant115025%Inflant115025%Inflant1161157Inflant1161157 <td< td=""><td></td><td>Black</td><td>265</td><td>6%</td></td<>		Black	265	6%
Pacific Islander1132%Other/Unknown1133%Cancer TypeHead, Neck, & Throat3037%Gastrointestinal135930%Respiratory98821%Bone, Skin, & Connective Tissue50111%Breast3648%Male Reproductive4199%Kidney & Bladder1844%Female Reproductive1844%Endocrine & Neuroendocrine521%Brain & CNS311%Bolod & Lymphatic3037%Year of Death2005-2009143131%2005-2009143131%2010-2014239952%TIM Stage at DiagnosisI115725%III115725%16%III115725%16%Single case without remission313925%Ordering Oncologists per Pati110cologists3130Inaging in the Final Year of Li10cologists3126%Imaging Ordered10924%20%20%Inaging Ordered10003126%Imaging Ordered10003007%Imaging Ordered10003057%Imaging Ordered3057%300Imaging Ordered3057%305Imaging Ordered3057%305Imaging Ordered3057%305Imaging Ordered3057%305Imagi		Asian	664	14%
Other/Unknown1483%Cancer Type984135930%Castrointestinal135930%Gastrointestinal135930%Gastrointestinal135930%Respiratory98821%Bone, Skin, & Connective Tissue50111%Breast3648%Male Reproductive1714%Female Reproductive1844%Endocrine & Neuroendocrine521%Bolod & Lymphatic2335%Year of Death2005-2009143131%2005-2009143131%31%2005-2009143131%31%2005-2009143131%31%2005-2009143131%31%2010-2014239952%TMM Stage at DiagnosisI115725%II115725%III115725%31%31%ISile case without remission31326%Cancer Recurrence110115725%Ordering Oncologists per Pati1115725%I10ncologist31126%230ncologists30%2%4 or More Oncologists902%Imaging in the Final Year Offici110315I1000logists30%7%4 or More Oncologists902%Imaging Ordered345775%No Imaging Ordered114%25%		Pacific Islander	113	2%
Cancer TypeHead, Neck, & Throat3037%Gastrointestinal30530%30%Gastrointestinal135930%31%RespiratoryBone, Skin, & Connective Tissue50111%Breast3648%4%Female Reproductive4199%Kidney & Bladder1844%Endocrine & Neuroendocrine521%Brain & CNS2335%Year of Death2335%Year of Death2005-20091431TMM Stage at Diagnosis111157TMM Stage at Diagnosis111157Cancer Recurrence111157In Conclogists per Path2005330Ordering Oncologists per Path111152In Conclogists31031%Anoclogists31023%Anoclogists31023%Anoclogists31023%Imaging Inthe Final Year1011%Kange Group10%20%Anoclogists10%31%Anoclogists10%31%Anoclogists10%31%Anoclogists10%31%Anoclogists10%31%Anoclogists10%31%Anoclogists10%31%Anoclogists10%31%Anoclogists10%31%Anoclogists10%31%Anoclogists31%31%Anoclogists31%31%Anoclogists </td <td></td> <td>Other/Unknown</td> <td>148</td> <td>3%</td>		Other/Unknown	148	3%
Head, Neck, & Throat3037%Gastrointestinal135930%Gastrointestinal135921%Respiratory98021%Bone, Skin, & Connective Tissue3648%Breast3648%Male Reproductive1714%Female Reproductive1844%Endocrine & Neuroendocrine521%Brain & CNS311%Bool & Lymphatic2103%Year of Death2005-2009143131%TNM Stage at Diagnosis11115725%II2005-2009143131%2010-201420912%15%Anton Stage at Diagnosis1115725%II115125%16%15%Ordering Oncologists per Patient10ncologists313023%Imaging in the Final Year of Death1115%25%Imaging Ordered31325%20%Imaging Ordered11%25%20%Imaging Ordered11%25%20%Imaging Ordered11%25%20%	Cancer Type			
Image: product of the section of th		Head, Neck, & Throat	303	7%
Respiratory98821%Bone, Skin, & Connective Tissue5011%Breast3648%Male Reproductive1499%Female Reproductive4199%Kidney & Bladder1844%Endocrine & Neuroendocrine521%Brain & CNS3131%Boole & Lymphatic2031%Year of Death2000-200477517%Year of Death2000-2004239952%TNM Stage at Diagnosis131%31%III2010-2014239952%TIM Stage at Diagnosis115%15%III115725%16%16%III115725%15%15%Ordering Oncologists per Patient10ncologists131268%Inaging in the Final Year30ncologists7%40Imaging Ordered10%311268%Imaging Ordered11%25%15%No Imaging Ordered11%25%15%No Imaging Ordered11%25%15%		Gastrointestinal	1359	30%
Bone, Skin, & Connective Tissue50111%Breast3648%Breast3648%Male Reproductive1714%Female Reproductive1844%Kidney & Bladder1844%Endocrine & Neuroendocrine521%Brain & CNS311%Bood & Lymphatic305%Year of Death2005-2009143131%Year of Death2005-2009143131%2005-2009143131%31%2010-2014239952%TMM Stage at Diagnosis1115725%III115725%10%1157Ordering Oncologists per PathSancer recurrence333627%Inaging conclogists per Path110cologists3126%Ar More Oncologists30030%2%30%Imaging in the Final Year of Line115%7%30%Manging Ordered34577%30%No imaging Ordered34575%36%		Respiratory	988	21%
Breast3648%Male Reproductive1714%Male Reproductive1714%Female Reproductive1809%Kidney & Bladder18018Endocrine & Neuroendocrine521%Brain & CNS311%Blood & Lymphatic2335%Year of Death2005-2009143031%2005-2009143131%2005-2009143131%2005-2009143131%II10-201415715%III115725%III115725%III115725%Ordering Oncologists per Patiett103132Inaging rin the Final Year3031%Imaging Ordered1002%Imaging Ordered15%7%Normaging Ordered3457%Normaging Ordered15%7%		Bone, Skin, & Connective Tissue	501	11%
Male Reproductive1714%Female Reproductive4199%Female Reproductive4199%Kidney & Bladder1844%Endocrine & Neuroendocrine521%Brain & CNS2135%Year of Death200-200477517%2005-2009143131%2010-20142081431TNM Stage at Diagnosis1115715%II115725%11%II115725%15%Ordering Oncologists per Patient2010-20142096Ordering Oncologists per Patient10ncologists3132I2010-2014313225%I115725%15%I3100209646%I2016311268%I2000-2054109024%I30ncologists15%7%Imaging in the Final Year of Li11%15%No Imaging Ordered345775%No Imaging Ordered11%25%		Breast	364	8%
Female Reproductive4199%Kidney & Bladder1844%Kidney & Bladder1844%Endocrine & Neuroendocrine521%Brain & CNS311%Brain & CNS311%Bool & Lymphatic311%Year of Death2005-2009143131%2005-2009143131%201-201430%TNM Stage at Diagnosis1110016%16%II1175016%11%25%IV20062006200620062006Cancer Recurrence111115725%25%IV20102016313073%Ordering Oncologists per Patient110ncologists3126%I30ncologists31025%31%31%I30ncologists10024%31%25%Imaging in the Final Year (Life1010%25%7%Imaging Ordered3457%7%7%Indiang Ordered114%25%15%15%		Male Reproductive	171	4%
Kidney & Bladder1844%Endocrine & Neuroendocrine521%Endocrine & Neuroendocrine521%Brain & CNS2335%Year of Death2000-20047751%2005-2009143131%2010-2014239952%TNM Stage at Diagnosis115%1%Inflammer7501%Inflammer115725%Inflammer115725%Inflammer136923%Cancer Recurrence1101369Ordering Oncologists per Patient200clogists312Inflammer3103126%2000-20153000-20143126%Anorologists10003126%Inflammer3102%30Inflammer3102%30Inaging in the Final Year Off116116Imaging Ordered34577%Normaging Ordered1165%		Female Reproductive	419	9%
Endocrine & Neuroendocrine521%Brain & CNS311%Brain & CNS311%Bood & Lymphatic201%Year of Death2000-20047751%2000-2004143131%2010-2014239952%TNM Stage at Diagnosis11%I175016%III115725%IV200646%Cancer Recurrence11%31%Single case without remission3126%Ordering Oncologists per Pathi10ncologists31126%2 Oncologists30030%7%A oncologists30%30%7%A ondore Oncologists90%7%6%Imaging Ordered10%31%5%No Imaging Ordered34575%No Imaging Ordered11%5%		Kidney & Bladder	184	4%
Brain & CNS311%Blood & Lymphatic2335%Year of Death2000-200477517%2005-2009143131%2010-201423952%TMM Stage at Diagnosis115%I10175016%III115725%Variance115725%ISING case without remission20946%Ordering Oncologists per Path1157I10cologists31025%I10cologists311268%20nologists30ncologists11025%Imaging in the Final Year1100024%Imaging Ordered100031125%No Imaging Ordered34575%No Imaging Ordered114825%		Endocrine & Neuroendocrine	52	1%
Blood & Lymphatic2335%Year of Death200-20047751%2005-20092039203920392005-2009203920392039TNM Stage at Diagnosis1100100TIM Stage at Diagnosis1115725%I11101002039I111025%25%I11023%25%Cancer Recurrence126027%23%Ordering Oncologists per Patiett12025%2220nclogists31024%330ncologists10024%330ncologists10024%Andore Oncologists10025%25%Imaging in the Final YearImaging Ordered3457%Normaging Ordered14625%25%		Brain & CNS	31	1%
Year of Death 2000-2004 775 17% 2005-2009 2130 31% 2005-2009 2030 2130 TNM Stage at Diagnosis 1 100 100 TIM Stage at Diagnosis 1 100 100 Cancer Recurrence 1 200 100 Ordering Oncologists per Patter 1 100 200 Ordering Oncologists per Patter 1 1000 200 Imaging in the Final Year 3 300 200 Imaging Ordered 000 200 200 Imaging Ordered 1000 100		Blood & Lymphatic	233	5%
2000-2004 775 17% 2005-2009 1431 31% 2010-2014 205 TNM Stage at Diagnosis 602 13% II 100 100 10% III 110 2056 10% Cancer Recurrence 111 25% 10% Cancer Recurrence 1339 73% Ordering Oncologists per Patient 10ncologists 312 6% 2 Oncologists 310 20% 20% A oncologists 310 25% 7% Imaging Ordered 00% 20% 20%	Year of Death			
2005-2009 1431 31% 2010-2014 2399 52% TNM Stage at Diagnosis 52% TNM Stage at Diagnosis 602 13% II 110 750 16% III 1157 25% IV 2096 46% Cancer Recurrence 75% Ordering Oncologists per Patient 10ncologists 312 6% 2 Oncologists 2096 20% 24% 3 Oncologists 310 25% Imaging in the Final Year of Life 10 7% Imaging Ordered 3457 75% No Imaging Ordered 1148 25%		2000-2004	775	17%
2010-2014239952%TNM Stage at DiagnosisI6021%II75016%1%IIII10115725%20%IIIV20%20%20%Cancer RecurrenceI130725%Ordering Oncologists per Path10ncologists31326%2 Oncologists2020%24%3 Oncologists30%25%7%Ard More Oncologists9057%Imaging Ordered345775%No Imaging Ordered114825%		2005-2009	1431	31%
TNM Stage at Diagnosis I 602 13% I If 750 16% II IT 25% 25% III 2000 2060 27% Cancer Recurrence 1266 27% Single case without remission 330 73% Ordering Oncologists per Patient 10ncologists 3112 68% 2 Oncologists 200 24% 200 24% 3 Oncologists 98 24% 7% Imaging in the Final Year of Life Imaging Ordered 3457 7% No Imaging Ordered 1148 25%		2010-2014	2399	52%
I 602 13% II 750 16% III 25% 25% V 2060 25% Cancer Recurrence 1266 27% Single case without remission 330 73% Ordering Oncologists per Patient 10ncologists 3112 68% 2 Oncologists 30ncologists 1090 24% 3 Oncologists 30 7% 30% Imaging in the Final Year of Life 1000 1000 24% No Imaging Ordered 98 25%	TNM Stage at Diagnosis			
II 750 16% III 1157 25% IV 200 640 Cancer Recurrence 1266 27% Single case without remission 3309 73% Ordering Oncologists per Patient 1 68% 2 Oncologists 3112 68% 3 Oncologists 300 24% 3 Oncologists 300 7% Imaging in the Final Year OH 10 24% Imaging Ordered 98 25%		I	602	13%
IIII1525%IV209646%Cancer Recurrence126027%Single case without remission130073%Ordering Oncologists per Patter10ncologists1101 Oncologists20024%2 Oncologists109024%3 Oncologists00024%3 Oncologists00027%Imaging in the Final YearImaging Ordered3457No Imaging Ordered114825%		II	750	16%
IV 2096 46% Cancer Recurrence Cancer Recurrence 120 3339 73% Single case without remission 312 8% Ordering Oncologists per Patient 1 0ncologists 1000 24% 2 Oncologists 3000 300 24% 3 Oncologists 300 30% 30% Imaging in the Final Year of Life 1000 24% No Imaging Ordered 3457 75%		III	1157	25%
Cancer Recurrence 126 273 Cancer recurrence 1303 273 Single case without remission 310 283 Ordering Oncologists per Patient 1 10ncologist 3112 683 2 Oncologists 20ncologists 1090 243 3 Oncologists 305 7% 4 or More Oncologists 9 20 Imaging Ordered 3457 75% No Imaging Ordered 1148 25%		IV	2096	46%
Cancer recurrence126627%Single case without remission333973%Ordering Oncologists per Patient118%110ncologist31126%220ncologists30024%30ncologists3057%4 or More Oncologists982%Imaging in the Final Year of LifeImaging Ordered345775%No Imaging Ordered114825%	Cancer Recurrence			
Single case without remission33373%Ordering Oncologists per Patient168%1 Oncologist10924%2 Oncologists10924%3 Oncologists982%4 or More Oncologists982%Imaging Ordered34577%No Imaging Ordered114825%		Cancer recurrence	1266	27%
Ordering Oncologists per Patient 1 Oncologist 3112 68% 1 Oncologists 2 Oncologists 1090 24% 2 Oncologists 3 Oncologists 7% 4 or More Oncologists 98 2% Imaging in the Final Year of Life Imaging Ordered 3457 75% No Imaging Ordered 1148 25%		Single case without remission	3339	73%
1 Oncologist 3112 68% 2 Oncologists 1090 24% 3 Oncologists 300 7% 4 or More Oncologists 98 2% Imaging in the Final Year of Life Imaging Ordered 3457 75% No Imaging Ordered 1148 25%	Ordering Oncologists per Patient			
2 Oncologists 1090 24% 3 Oncologists 30 2% 4 or More Oncologists 2% Imaging in the Final Year of Life Imaging Ordered 3457 75% No Imaging Ordered 1148 25%		1 Oncologist	3112	68%
3 Oncologists3057%4 or More Oncologists982%Imaging in the Final Year of LifeImaging Ordered345775%No Imaging Ordered114825%		2 Oncologists	1090	24%
4 or More Oncologists 98 2% Imaging in the Final Year of Life Imaging Ordered 3457 75% No Imaging Ordered 1148 25%		3 Oncologists	305	7%
Imaging in the Final Year of Life Imaging Ordered 3457 75% No Imaging Ordered 1148 25%		4 or More Oncologists	98	2%
Imaging Ordered345775%No Imaging Ordered114825%	Imaging in the Final Year of Life			
No Imaging Ordered 1148 25%		Imaging Ordered	3457	75%
		No Imaging Ordered	1148	25%

Table 2

Patient Frequency Distribution of Total Treatments by Treatment Type.

Number of Treatments			
6			
0			
0			
5			

3. Results

3.1. Descriptive statistics

The patient population was comprised of 4,605 patients with 29,740 tomographic imaging studies ordered by oncologists. CT accounted for 67.5% of tomographic imaging (n=20,083); MR accounted for 19.5% (n=5,782); and PET accounted for 13% (n=3,875). Patient demographics and cancer characteristics may be found in Table 1. Table 2 provides frequencies of surgery, radiation, and chemotherapy treatments. All patients had at least one of the three treatment types. Mean tomographic imaging intensity from diagnosis to death was 6.46 imaging studies per patient [standard deviation (SD) = 7.89], and mean imaging in the final year of life

Download English Version:

https://daneshyari.com/en/article/5701359

Download Persian Version:

https://daneshyari.com/article/5701359

Daneshyari.com